Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple myeloma

Showing 15 posts of 81 posts found.

Overcoming real-world challenges to maximise the benefit of treatment for patients with multiple myeloma

October 2, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Takeda, multiple myeloma

Dr Antonio Palumbo, Distinguished Research Fellow Oncology, Takeda Pharmaceuticals addresses hwo far we’ve come in treating multiple myeloma, and how …

Feature
8224204466_e6b23e80e6_z

Rabbit virus proves effective in treatment of multiple myeloma

February 22, 2017
Research and Development multiple myeloma

A team of researchers at the Medical University of South Carolina (MUSC) utilising the myxoma virus (MYXV) to treat multiple …

News
revlimid_celgene

Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU

January 27, 2017
Sales and Marketing Celgene, Revlimid, multiple myeloma

Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …

News
takeda_tokyo_hq

Takeda gains marketing authorisation for multiple myeloma pill

November 28, 2016
Sales and Marketing Takeda, multiple myeloma

Takeda Pharmaceutical has announced that they have received conditional marketing authorisation for Ninlaro (ixazomib) for treatment of adult patients with …

News
jj_2johnson_and_johnson

J&J and Genmab’s drug races to second line treatment approval

November 22, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma

Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …

News
celgene_1_02

$600m acquisition bolsters Celgene’s blood cancer portfolio

October 3, 2016
Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma

Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …

News
janssen_latest_logo_on_sign_closer

Darzalex receives breakthrough designation in multiple myeloma from FDA

July 26, 2016
Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …

News
janssen_latest_logo_on_sign

Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma

June 10, 2016
Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma

Janssen said late-stage combination trials for its immunotherapy daratumumab increased progression-free survival for patients with multiple myeloma.  The company said …

News
amgen_flag

Amgen showcases positive Phase III multiple myeloma drug at ASCO

June 7, 2016
Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma

Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …

News
janssen_latest_logo_on_sign_closer

Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS

June 6, 2016
Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma

Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival.  The company …

News
janssen_latest_logo_on_sign

Genmab receives milestone payment for first Darzalex sale in Europe

May 31, 2016
Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales

Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …

News

Multiple myeloma treatment from BMS and AbbVie scores EU approval

May 12, 2016
Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma

Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …

News
janssen_latest_logo_on_sign_closer

Two CHMP nods for Janssen

April 4, 2016
Research and Development, Sales and Marketing Xeplion, darzalex, multiple myeloma

The European Commission’s scientific committee has recommended Janssen’s Darzalex (daratumumab) for multiple myeloma and Trevicta (paliperidone palmitate) for maintenance treatment …

News
cancer_cells

Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours

March 22, 2016
Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …

News
amgen_flag

Amgen’s Kyprolis now available to UK multiple myeloma patients

February 12, 2016
Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma

Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026